ReviewNatural product reports2026
Cultivar to chemotype: characterizing complex botanicals with mass spectrometry metabolomics.
Review in Natural product reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Chemical Ontogeny in Plants: Developmental Dynamics of Specialized Metabolism and Implications for Ecology, Quality Control, and Bioprospecting.Plants (Basel, Switzerland) · 2026Review
- Multi-Platform Metabolomics for Fraud Detection in Spices and Botanical Food Supplements: From Fingerprint Acquisition to Decision-Grade Evidence.Molecules (Basel, Switzerland) · 2026Review
- Metabolomic Profiling Reveals Geographical Origin, Tissue-Specific Specialization, and Environmental Plasticity in Secondary Metabolism ofMetabolites · 2026Article
- Harnessing engineered cyanobacteria for next-generation therapeutics.Archives of microbiology · 2026Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Covering up to 2025Plant products, including botanical dietary supplements, nutraceuticals, and herbal medicines, remain central to supporting human health and wellness. Their usage has been steadily increasing over the last few decades, which has also led to raised concerns about proper identification and characterization of plant materials. This information is crucial to evaluate the safety and efficacy of these botanical products and prevent misidentification or adulteration. While there are multiple analytical approaches to characterize botanicals, this review provides insight into how untargeted mass spectrometry metabolomics can profile these commonly complex mixtures and provide detailed datasets that are capable of taxonomically classifying samples, detecting adulteration, and providing insight into variation between plant materials and their nutritional, medicinal, or toxicological effects. We describe data analysis approaches for untargeted metabolomics, case studies on the various applications of this method for characterizing botanicals, and challenges that the growing field of mass spectrometry-based metabolomics is facing. The chosen topics reflect the current state of metabolomics analyses for complex systems with a look to the future of how to conceptualize botanical characterization.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.